Results 61 to 70 of about 18,775 (216)

HierAnom‐Path: Zero‐Shot Rare Cancer Detection in Histopathology via Hierarchical Foundation Model Adaptation

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Rare cancers collectively represent 20%–25% of all malignancies yet yield fewer than 50 annotated whole‐slide images (WSIs) per subtype in publicly available archives, rendering supervised deep learning inapplicable. We present HierAnom‐Path, to the best of our knowledge, the first framework for zero‐shot rare cancer anomaly detection in ...
Noora Saleem Jumaah, Mohanad Sameer Jabbar, Saif H. Alwaeli, Noor Ayesha, Mohamed Babiker A. Mohamed, Muhammad I. Khan   +5 more
wiley   +1 more source

Prostatic Carcinosarcoma with Lung Metastases [PDF]

, 2013
Carcinosarcoma of the prostate is an uncommon malignancy with poor long-term prognosis. The cancer is typically discovered at an advanced stage, and with less than 100 reported cases, there is limited literature concerning treatment options.
David J. Kang, Armando Armas, Stefanie R. Furlan   +2 more
core   +1 more source

A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterine serous carcinoma or carcinosarcoma

BMC Medicine
Background Uterine serous carcinoma and carcinosarcoma are aggressive forms of endometrial cancer with poor survival outcomes. Trastuzumab, a human epidermal growth factor receptor-2 (HER2)-directed monoclonal antibody, has demonstrated tumoricidal ...
Ting-Fang Lu, Lou Sun, Yu-Hsiang Shih, Yen-Fu Chen, Chun-Ting Fan, Shao-Jing Wang, Shih-Tien Hsu, Chih-Ku Liu, Sheau-Feng Hwang, Chien-Hsing Lu   +9 more
doaj   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Trends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database

, 2023
Carcinosarcomas (malignant mixed Mullerian tumors) of a female genital organ are rare tumors associated with a poor survival. The purpose of this study was to identify site-specific differences in the incidence and prognosis in carcinosarcomas ...
Jae-Kwan Lee, Jae-Yun Song, Sanghoon Lee, Joo Won Lee, Kyung-Jin Min, Ha Kyun Chang, Nak Woo Lee, Jin-Hwa Hong, Yung-Taek Ouh, Min, Kyung-Jin, Ouh, Yung-Taek, Lee, Jae-Kwan, Lee, Nak Woo, Chang, Ha Kyun, Hong, Jin-Hwa, Lee, Joo Won, Lee, Sanghoon, Song, Jae-Yun   +17 more
core   +1 more source

Ovarian Carcinoma: Signal Pathways and Clinical Studies

MedComm, Volume 7, Issue 11, November 2026.
This review synthesizes current knowledge on the pathophysiological mechanisms driven by the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways in ovarian cancer. A key focus is placed on summarizing subsequent targeted therapeutic strategies, detailing the landscape of associated clinical trials and their ...
Yanru Long, Houhui Shi, Jiatian Ye, Xiaorong Qi   +3 more
wiley   +1 more source

Ovarian carcinosarcoma in a perimenopausal woman

, 2023
El carcinosarcoma de ovario, o tumor mixto de Müller, es una neoplasia infrecuente que representa alrededor del 1 al 4% de los carcinomas ováricos epiteliales. Su histología combina componentes sarcomatosos y carcinomatosos.
Rodríguez Sánchez Reyman, Julia, Rodríguez Jiménez, Inmaculada, Gutiérrez Domingo, Álvaro, Pantoja Garrido, Manuel, Luque González, Pablo   +4 more
core   +1 more source

A rare malignant thyroid carcinosarcoma with aggressive behavior and DICER1 gene mutation: a case report with literature review

Thyroid Research, 2018
Background Malignant biphasic tumor also known as carcinosarcoma is an uncommon neoplasm that is composed of both malignant epithelial and mesenchymal components. Most reported cases of carcinosarcoma affect the female genital tract; however, other sites
Jing Yang, Carmen Sarita-Reyes, David Kindelberger, Qing Zhao   +3 more
doaj   +1 more source

A Case of Significant Response to Olaparib in a Patient with Primary Peritoneal Carcinosarcoma Diagnosed by Laparoscopic Surgery

Case Reports in Obstetrics and Gynecology, 2020
Primary peritoneal carcinosarcomas which arise from extragenital locations are extremely rare. Carinosarcomas contain both carcinomatous and sarcomatous elements and can be mainly detected in the female genital tract.
Satoshi Nagamata, Yukiko Nakasuji, Keitaro Yamanaka, Maho Azumi, Keiichi Washio, Maho Shimizu, Ryosuke Takahashi, Kazuyo Matsumoto, Yuka Murata, Kaho Suzuki, Masashi Deguchi, Hideto Yamada, Yoshito Terai   +12 more
doaj   +1 more source

Ultrasonography (IOTA‐ADNEX) vs magnetic resonance imaging (ADNEX MR) for diagnosing ovarian cancer in high‐risk patients: a prospective study

Ultrasound in Obstetrics &Gynecology, Volume 68, Issue 5, Page 701-713, November 2026.
ABSTRACT ObjectivesTo systematically validate and compare ultrasonography, using the ultrasound‐based International Ovarian Tumor Analysis – Assessment of Different NEoplasias in the adneXa (IOTA‐ADNEX) model, with magnetic resonance imaging (MRI), using the MRI‐based ADNEX MR scoring system, as second‐line imaging modalities for estimating the risk of
I. M. Dueholm Hjorth, A. Ledger, C. Møller, B. H. Bech, T. Van den Bosch, O. Mogensen   +5 more
wiley   +1 more source